Transforming the Treatment of Immune Diseases
Noa Therapeutics is a preclinical biotech company pioneering the development of multimodal therapies. Singular, non-steroidal, small molecules with tunable activity across three inflammatory barrier disease drivers to simplify the course of care for patients in need.
Breaking Free from Convention
Our immune system’s first line of defense are barriers such as our skin and gut. Impaired barrier function is associated with infection and inflammation, resulting in immune disease.
Current therapeutics for inflammatory barrier diseases focus on symptom relief, particularly inflammation due to the pathophysiological role of inflammatory cytokines in many diseases. However, addressing individual disease drivers in isolation inherently leads to limited efficacy, resulting in poor patient compliance, and unfortunately serious side effects. This current paradigm leaves patients and physicians cycling through trial-and-error treatment failures.
Noa is embarking on a journey to develop breakthrough multimodal therapeutics to wholly address the complexity of immune diseases. Providing singular therapeutic solutions with meaningful outcomes.
Our Approach
Leveraging a computer assisted drug discovery engine, Noa is leading the discovery of multimodal therapeutic compounds for the tailored treatment of immune diseases. Our suite of singular, non-steroidal, small molecules drive three discrete therapeutic targets, uniquely suited to address the complexity of immune diseases involving barrier dysfunction.
This differentiated multimodal approach is uniquely suited to address unmet needs in atopic dermatitis as a first use case. By addressing multiple disease drivers and providing an anticipated superior safety profile, Noa is aligned to serve underrepresented and underserved patients inclusive of juvenile and pediatric populations. Creating an opportunity for Noa to redefine immune disease treatment for unprecedented clinical impact.
The Impact of Atopic Dermatitis
Adults
Children
Persons affected by Atopic Dermatitis in the United States
%
Mild/Moderate
%
Dissatisfaction
Our Research
Noa Therapeutics is pioneering the development of non-steroidal, multimodal small molecules for the tailored treatment of complex immune diseases involving barrier dysfunction. Adopting a computer assisted drug discovery engine, Noa is working to tune the efficacy profile of their novel drug compounds to address persistent unmet needs, delivering meaningful therapeutics to underrepresented and underserved patients.
Immune Modulation
Attenuating inflammatory cytokines to promote resolution of chronic inflammation and immune homeostasis
Barrier Restoration
Upregulating epithelial and endothelial barrier proteins for the restoration of homeostatic barrier function
Microbiome Modulation
Broad spectrum antimicrobial efficacy, including antibiotic resistant pathogens, while retaining a null resistance profile
With an expected distinction in safety profile and multimodal therapeutic advantage, Noa aims to provide a long-term solution for the safe, effective, and rapid resolution of immune disease including juvenile and pediatric populations.
Delivering meaningful outcomes for all patients and those who care for them.
Our Program
Noa Therapeutics is a preclinical biotech company leveraging a computer assisted drug discovery engine to accelerate the design of tailored multimodal solutions for complex immune diseases involving barrier dysfunction.
Leveraging this differentiated approach, Noa’s non-steroidal lead drug compound, NOA-104, aims to simultaneously target three disease drivers to address persistent unmet needs within inflammatory barrier diseases. Noa is advancing a first use case in Atopic Dermatitis, with the potential for expansion into secondary dermatological inflammatory diseases. In parallel, Noa is building a portfolio of novel multimodal therapeutics to address systemic inflammatory disease markets including gastrointestinal (ulcerative colitis), central nervous system (multiple sclerosis), ocular, and cardiovascular indications.
Breaking free from the current treatment paradigm, Noa aims to resolve multiple immune diseases drivers. Restoring barrier function while promoting immune homeostasis without compromising systemic immunity. Streamlining treatment into one, singular, therapeutic solution with meaningful outcomes.
Team
C-Suite
Carla Spina PhD
CEO & Co-Founder
Founding Director. Seasoned innovator. Over 18 years experience in skin and wound device and drugs. Leading discovery through clinical phase study and commercialization.
Serena Mandla P.Eng, MASc
CSO & Co-Founder
Experienced innovator in the development, manufacturing, and commercialization of novel small peptides for cardiovascular and skin disease applications.
Board of Directors
Maura Campbell PhD
CEO at Ontario Bioscience Innovation Organization
François Ravenelle
CEO & President at Inversago Pharma